Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$429.19 USD

429.19
266,441

-1.18 (-0.27%)

Updated Aug 7, 2025 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (97 out of 244)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why Investors Should Hold Encompass Health (EHC) Now

by Zacks Equity Research

Encompass Health (EHC) remains well-poised for growth, attributable to expanding patient admissions, robust expansion endeavors and strong cash-generating abilities.

Zacks Equity Research

Here's Why You Should Hold Elevance (ELV) in Your Portfolio

by Zacks Equity Research

Improving top line, investments in high-growth businesses, membership hikes and significant new contracts in its government business poise Elevance Health (ELV) well for growth.

Zacks Equity Research

Here is Why Growth Investors Should Buy Medpace (MEDP) Now

by Zacks Equity Research

Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)

by Zacks Equity Research

Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

New Strong Buy Stocks for May 3rd

by Zacks Equity Research

COCO, RYI, GTX, MEDP and SKX have been added to the Zacks Rank #1 (Strong Buy) List on May 3rd, 2023.

Zacks Equity Research

All You Need to Know About Medpace (MEDP) Rating Upgrade to Strong Buy

by Zacks Equity Research

Medpace (MEDP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Medpace (MEDP) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Medpace (MEDP) delivered earnings and revenue surprises of 28.98% and 8.37%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TRxADE (MEDS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

TRxADE (MEDS) delivered earnings and revenue surprises of -66.67% and 8.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Medpace (MEDP) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Medpace (MEDP) delivered earnings and revenue surprises of 19.10% and 2.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Avantor, Inc. (AVTR) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Avantor, Inc. (AVTR) delivered earnings and revenue surprises of 6.67% and 0.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Acadia Healthcare (ACHC) Up 42% in a Year: More Room to Run?

by Zacks Equity Research

Acadia Healthcare (ACHC) is well-poised for growth on a diversified healthcare treatment network resulting from growth-related efforts.

Zacks Equity Research

Ensign Group (ENSG) Unveils Dividend Hike to Reward Shareholders

by Zacks Equity Research

Ensign Group's (ENSG) latest dividend hike reflects strong financial standing and intensified focus in the tactical deployment of capital.

Zacks Equity Research

Zacks Industry Outlook Highlights Medpace, HealthEquity and Progyny

by Zacks Equity Research

Medpace, HealthEquity and Progyny have been highlighted in this Industry Outlook article.

Zacks Equity Research

HCA Healthcare's (HCA) ESR Program Aids Post-Surgery Recovery

by Zacks Equity Research

HCA Healthcare's (HCA) ESR program remains on track to attract more patients to choose HCA's healthcare facilities for undergoing surgeries.

Urmimala Biswas headshot

3 Medical Services Stocks to Buy Amid Industry Challenges

by Urmimala Biswas

The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and PGNY are set to gain the most. However, staffing shortages may disrupt the trend.

Zacks Equity Research

Here's Why Investors Should Retain LabCorp (LH) Stock for Now

by Zacks Equity Research

Investors are optimistic about LabCorp (LH), led by strength in its Drug Development business.

Zacks Equity Research

HealthEquity (HQY) Stock Falls 1.6% Despite Q3 Earnings Beat

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs besides recording robust performances in all its segments in the third quarter of fiscal 2023.

Zacks Equity Research

Quest Diagnostics' (DGX) New Deal to Extend Laboratory Access

by Zacks Equity Research

Quest Diagnostics' (DGX) new collaboration with Northern Light Health will enhance access to diagnostics services in Maine.

Zacks Equity Research

Quest Diagnostics (DGX) Volume Growth Aids, Margin Woes Stay

by Zacks Equity Research

Quest Diagnostics' (DGX) legacy base business is growing amid softer utilization trends.

Zacks Equity Research

Thermo Fisher (TMO) End Markets Grow Strong, Margin Woe Stays

by Zacks Equity Research

Thermo Fisher (TMO) witnesses strength in three of its four end markets, categorized either by customer type or geography.

Zacks Equity Research

Ensign Group (ENSG) Facility Buyout to Boost Colorado Foothold

by Zacks Equity Research

Ensign Group (ENSG) acquires two skilled nursing facilities in Colorado that are likely to grow its healthcare portfolio and solidify its nationwide presence.

Zacks Equity Research

Veeva Systems (VEEV) Beats on Q3 Earnings, Revises FY23 View

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal Q3 results reflect impressive performances by both of its segments.

Zacks Equity Research

NextGen (NXGN) Buys TSI Healthcare to Boost Ambulatory Services

by Zacks Equity Research

NextGen (NXGN) acquires TSI Healthcare which may further solidify NXGN's position in the ambulatory healthcare space.

Zacks Equity Research

Patterson Companies (PDCO) Q2 Earnings Beat, Sales Hurt by FX

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal second-quarter 2023 results reflect unfavorable currency movements.

Zacks Equity Research

Molina Healthcare (MOH) Up 11% in 6 Months: More Room to Run?

by Zacks Equity Research

Molina Healthcare (MOH) is well-poised for growth on growing premiums, membership increases in Government business and sufficient cash reserves.